Breaks Categories: News

ThursdayAug 13, 2026 9:50 am

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) CEO to Present at 2026 Georgia Life Sciences Summit

Nutriband (NASDAQ: NTRB) announced that CEO and Co-Founder Gareth Sheridan will present as part of the CEO Spotlight event at the 2026 Georgia Life Sciences Summit on Aug. 26. The summit, scheduled for Aug. 25-26 at the Sandy Springs Performing Arts Centre in Sandy Springs, Georgia, brings together leaders across biotechnology, medical technology, research, manufacturing and investment. Nutriband is developing AVERSA (TM), its abuse-deterrent transdermal technology designed to incorporate aversive agents into patches to help prevent abuse, diversion, misuse and accidental exposure involving drugs with abuse potential. To view the full press release, visit https://ibn.fm/Un3ax About Nutriband Inc. We are primarily…

Continue Reading

WednesdayAug 12, 2026 12:02 pm

BioMedNewsBreaks — VolitionRx (NYSE American: VNRX) Reports Strong Correlation for Finger-Prick Nu.Q NETs Prototype in Sepsis Patients 

VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, announced that results using its lateral flow finger-prick prototype were highly correlated with results from its established automated Nu.Q NETs test in critically ill sepsis patients, supporting the potential expansion of nucleosome testing beyond centralized laboratories. The company said the lateral flow test could enable rapid identification of high-risk patients in emergency rooms or at the bedside, with testing showing a Spearman correlation of 0.85 and Pearson correlation of 0.881 compared with its CE-marked laboratory assay. The study, part of the SUMMIT program, evaluated capillary blood and plasma samples from intensive care patients and demonstrated significant correlation between…

Continue Reading

TuesdayAug 11, 2026 2:57 pm

BioMedNewsBreaks — Nano-X Imaging Ltd. (NASDAQ: NNOX) Optimizes Nanox.AI Medical Imaging Framework for Intel Core Ultra Processors 

Nano-X Imaging Ltd. (NASDAQ: NNOX) announced that subsidiary Nanox AI Ltd. has optimized its medical imaging AI application framework for Intel Core Ultra processors using Intel OpenVINO toolkit. The framework is designed to enable healthcare facilities to evaluate and deploy CT imaging AI applications on on-premise edge devices while keeping imaging data within their own infrastructure. Nanox.AI solutions analyze routine CT scans to help identify findings correlated with chronic conditions involving cardiac, liver and bone health. The optimized framework successfully ran inference on Intel Core Ultra-class hardware using OpenVINO, demonstrating its suitability for on-premise medical imaging AI processing. Nanox.AI said the approach can bring AI-enabled imaging insights closer to the point of care, while local edge inference…

Continue Reading

TuesdayAug 11, 2026 1:35 pm

BioMedNewsBreaks — AOM Capital Completes $5.1 Million Financing for Therapeutics Company Acquisition 

AOM Capital announced the completion of a $5.1 million financing for a therapeutics company in connection with its acquisition of a pharmaceutical drug asset. The private investment and specialty bridge lending firm structured the financing around the specific requirements of the transaction, providing the capital needed to support the acquisition. AOM Capital said the transaction expands its activity in private credit, acquisition financing and special situations, with the firm focused on providing flexible capital for acquisitions, bridge transactions, growth initiatives and other complex or time-sensitive opportunities. To view the full press release, visit https://ibn.fm/imbdB About AOM Capital AOM Capital is a private investment and specialty bridge…

Continue Reading

MondayAug 10, 2026 9:10 am

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Receives FDA Clearance to Advance Lucid-MS into Phase 2

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced that the U.S. Food and Drug Administration has approved its Investigational New Drug (“IND”) application for Lucid-MS (Lucid-21-302), clearing the company to advance the patented, first-in-class multiple sclerosis candidate into Phase 2 clinical development. The planned randomized, double-blind, placebo-controlled study will evaluate efficacy, safety and tolerability in people with MS using clinical and radiological measures. Trial start-up activities, including site selection, are underway, with patient enrollment and drug administration expected to begin as quickly as possible. Lucid-MS…

Continue Reading

MondayAug 10, 2026 9:00 am

BioMedNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Q2 Revenue of $13.5 Million as TONMYA Sales Reach $11 Million

Tonix Pharmaceuticals (NASDAQ: TNXP) reported second-quarter 2026 net product revenue of approximately $13.5 million, up from $2 million in the year-ago period, driven by approximately $11 million in net sales of TONMYA. The fibromyalgia treatment recorded 12,592 total prescriptions during the quarter, up 100% sequentially, while new patient prescriptions increased 36% and refills rose 207%. TONMYA currently has coverage representing approximately 136 million lives across commercial, managed Medicare and Medicaid channels, with coverage expected to reach approximately 145 million lives when a managed Medicare agreement takes effect Jan. 1, 2027. Tonix also continued advancing its clinical pipeline, enrolling the first…

Continue Reading

FridayAug 07, 2026 9:20 am

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Reports 57% Increase in Fiscal First-Quarter Net Income

Earth Science Tech (OTC: ETST) reported fiscal first-quarter 2027 results highlighted by a 57% year-over-year increase in net income to $715,697 on revenue of $9.0 million, up 3% from the prior-year period. Gross profit rose to $6.3 million, operating cash flow more than doubled to $707,131 and total assets increased to $10.4 million. Diluted earnings per share improved to $0.003 from $0.001, while the company repurchased and retired more than 3.7 million common shares during the quarter without adding debt. The company said all key operating subsidiaries remained profitable as it continued expanding the licensing footprint of its compounding pharmacy…

Continue Reading

WednesdayAug 05, 2026 12:26 pm

BioMedNewsBreaks — VolitionRx (NYSE American: VNRX) Publishes Peer-Reviewed Capture-Seq Study 

VolitionRx Limited (NYSE American: VNRX) announced the publication of the first peer-reviewed paper detailing its proprietary Capture-Seq liquid biopsy technology, which the company said is the first to isolate and analyze more than 99% pure circulating tumor-derived DNA ("ctDNA"). According to the publication, the technology addresses a longstanding challenge in liquid biopsy by separating cancer-derived DNA from the large background of healthy cell-free DNA, creating highly enriched tumor DNA datasets for cancer detection and monitoring. Volition said it is conducting technical evaluations with potential licensing partners and estimates the technology addresses annual market opportunities of approximately $23 billion for multi-cancer early detection and more than $13 billion for…

Continue Reading

TuesdayAug 04, 2026 1:25 pm

BioMedNewsBreaks — SRX Global Inc. (NYSE American: SRXH) Acquires Stake in Vistagen Therapeutics 

SRX Global (NYSE American: SRXH) announced that it has acquired a stake in Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company developing intranasal neuroscience therapies based on its proprietary pherine platform. SRX said the investment aligns with its strategy of creating long-term shareholder value through investments in high-conviction operating companies and strategic assets. SRX said it believes Vistagen shares are undervalued and intends to engage constructively with the company's leadership team and board of directors to discuss opportunities to unlock shareholder value. To view the full press release, visit https://ibn.fm/VFyBI About SRX Global Inc. SRX Global is an AI-driven platform focused on generating long-term shareholder value through investments in high-conviction…

Continue Reading

MondayAug 03, 2026 9:50 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) to Present at OTCQB Virtual Investor Conference

Oncotelic Therapeutics (OTCQB: OTLC) announced that CEO and Chairman Dr. Vuong Trieu will present at the OTCQB Virtual Investor Conference on Aug. 6, 2026, at 2:30 p.m. ET, where investors will have the opportunity to participate in a live question-and-answer session. The company will highlight recent progress, including advancement of its Phase 1b intravenous Everolimus (Sapu003) trial to the next dose cohort, expansion of European clinical sites, validation of its Deciparticle(TM) platform through peer-reviewed publications, scalable cGMP manufacturing capabilities and continued development of its AI-driven drug discovery, robotics and nanomedicine platforms. To view the full press release, visit https://ibn.fm/fGHUt About…

Continue Reading